Find Funding Opportunities

The purpose of this Funding Opportunity Announcement (FOA) is to support the creation of a research resource infrastructure for the administration of research investigations using person-centered health outcomes, further referred to as the Person-Centered Outcomes Research Resource (PCORR). The overarching goal for the PCORR will be to facilitate person-centered outcome research by supporting the use and enhancements of the following four measurement information systems, currently funded as separate NIH programs: the the Patient Reported Outcomes Measurement Information System (PROMIS: http://www.nihpromis.org/); the NIH Toolbox for Assessment of Neurological and Behavioral Function (NIH Toolbox: http://www.nihtoolbox.org/); the Quality of Life (QOL); Outcomes in Neurological Disorders (Neuro-QOL: http://www.neuroqol.org/); and the Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me: http://www.air.org/files/4_pager_AIR_Health_Polict_2011_V10F.pdf).

This Funding Opportunity Announcement (FOA) encourages research grant applications to characterize the role of stigma in health, life course development, and aging, both in the U.S. and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, health care system, and policy levels. The goal of this FOA is to promote research addressing the health-related aspects of stigma, including the etiology and perpetuation of stigma; its impact on physical and mental health, well-being, life course development, and aging; its influence on health behaviors and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-related stigma and/or the negative health and life course developmental impacts of stigma.

This Funding Opportunity Announcement (FOA) encourages research grant applications to characterize the role of stigma in health, life course development, and aging, both in the U.S. and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, health care system, and policy levels. The goal of this FOA is to promote research addressing the health-related aspects of stigma, including the etiology and perpetuation of stigma; its impact on physical and mental health, well-being, life course development, and aging; its influence on health behaviors and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-related stigma and/or the negative health and life course developmental impacts of stigma.

The purpose of this funding opportunity announcement is to request applications for the initiation or continuation of nationally-available neuroscience research education programs that will significantly advance the mission of NINDS.

This Funding Opportunity Announcement (FOA) reissued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA) and the Administration for Children and Families (ACF) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH, CDC, FDA or ACF awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2013-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, FDA and ACF.

This Funding Opportunity Announcement (FOA) reissued by the National Institutes of Health (NIH) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2013-2 SBIR/STTR Program Descriptions and Research Topics for NIH.)

This Funding Opportunity Announcement (FOA) encourages exploratory and developmental grant applications to lay the foundation for innovative and collaborative basic research on the role of epigenetics in social, behavioral, environmental and biological relationships, throughout the life-span and across generations. Research plans that are responsive to this FOA will use existing bio-psycho-social and environmental data from human cohorts or animal studies that have biospecimens available for epigenetic profiling. The one year exploratory/developmental awards are expected to generate preliminary data for comprehensive basic research applications to study interactions between epigenetics and social/behavioral/biological/environmental factors in both normal function and pathophysiology throughout life and across generations. The results may ultimately inform research to develop clinical decision/diagnostic tools and prevention/treatment strategies.

This Funding Opportunity Announcement (FOA) encourages research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to autism spectrum disorders (ASD). Basic, clinical, and applied studies are encouraged.

This Funding Opportunity Announcement (FOA) encourages research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to autism spectrum disorders (ASD). Basic, clinical, and applied studies are encouraged. The R21 grant mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on biomedical, behavioral, or clinical research.

This Funding Opportunity Announcement (FOA) encourages grant applications for Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01s). The mission of the CounterACT U01 program is to develop new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, and pesticides. Applicants are encouraged to contact the Program Officials listed in this FOA to determine if their proposed threat agent(s) or countermeasure(s) is of high program priority for one of the participating Institutes. The scope of the research to be supported includes target and candidate identification and characterization, through candidate optimization and demonstration of in vivo efficacy, through Investigational New Drug (IND) submission when appropriate. Each project must include milestones that create discrete go or no-go decision points in a progressive translational study plan.